Evaluation of Annexin A1 Protein in an Infectious Keratitis Model: Therapeutic Perspectives
- Pseudomonas aeruginosa,
- Ocular inflammation
Copyright (c) 2019 Da Silva et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Introduction: bacterial keratitis caused by Pseudomonas aeruginosa is one of the causes of blindness in the world, due to pathogenicity of the bacteria that can lead to corneal perforation. Studies on the protein annexin A1 (AnxA1) point it as one of the essential mediators in homeostasis of inflammation and ocular infections. However, there are no known reports of AnxA1 in keratitis.
Objetive: to investigate the expression profile of AnxA1 in the P. aeruginosainduced keratitis model in two strains of mice (susceptible and pathogen resistant).
Method: for the development of experimetal keratitis, the mice had their right eyes ulcerated and immediately inoculated with 5 μl of P. aeruginosa in PBS. The animals were euthanized after 24 hours of the bacteria inoculation. The eyes were clinically evaluated and histopathologically processed for quantitative analyses of the inflammatory infiltrate and immunohistochemical studies of the expressions of the AnxA1 and the receptor for formylated peptides (fpr2).
Results: our results demonstrated a higher influx of inflammatory cells, mainly neutrophils in the susceptible animals (C57BL / 6) compared to those considered resistant (BALB / c) and controls. Immunohistochemical studies indicated weak expression of AnxA1 and fpr2 in the anterior epithelium and stroma of the cornea. However, after keratitis induction, overexpression of AnxA1 and fpr2 occurred in the corneas of both mice strains. Furthermore, greater expression of AnxA1 in the anterior corneal epithelium was observed in the C57BL / 6 animals.
Conclusions: AnxA1 and fpr2 may be related to infectious keratitis induced by P.aeruginosa, which stimulates further investigations on the use of AnxA1 as a possible coadjuvant therapeutic strategy in bacterial keratitis.